Dyslipidemias and fibrinolysis

Italian Heart Journal

Volumn 3, Issue 10, 2002, Pages 579-586

  Puccetti, Luca ^a   Bruni, Fulvio ^a   Pasqui, Anna Laura ^a   Pastorelli, Marcello ^a   Bova, Giovanni ^a   Cercignani, Michela ^a   Palazzuoli, Alberto ^a   Auteri, Alberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPOPROTEIN; PADGEM PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VON WILLEBRAND FACTOR;

ADULT; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; REVIEW; VEIN OCCLUSION;

ADULT; E-SELECTIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN PRECURSORS; PROTHROMBIN; VON WILLEBRAND FACTOR;

EID: 0036818394     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Haemost 1990; 16: 207-12.
2. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-3.
3. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1992; 332: 635-41.
4. Gough S, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabet Med 1991; 8: 898-905.
5. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with the extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
6. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost 1989; 61: 370-3.
7. Cimminiello C, Vigorelli P, Piliego T, et a]. Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol. Biomed Pharmacother 1997; 51: 164-9.
8. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995; 74: 626-30.
9. Metha J, Metha P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary disease: correlation with age and serum triglyceride concentration. J Am Coll Cardiol 1987; 9: 263-8.
10. Mussoni L, Mannucci L, Sirtori C, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27.
11. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani GD. Fibrinolysis in hypertrygliceridaemic subjects in response to venous occlusion. Blood Coagul Fibrinolysis 1993; 4: 429-33.
12. Avellone G, Di Garbo V, Cordova R, et al. Activation of coagulation but normal fibrinolysis in patients with type IIa hyperlipoproteinemia. Thromb Res 1996; 81: 277-82.
13. Hiraga T, Shimada M, Tsukada T, Murase T. Hypertriglyceridemia but not hypercholesterolemia is associated with the alterations of the fibrinolytic system. Horm Metab Res 1996; 28: 603-6.
14. Alessandri C, Basili S, Maurelli M, et al. Relationship between prothrombin activation fragment F1+2 and serum cholesterol. Haemostasis 1996; 26: 214-9.
15. Aoki I, Aoki N, Kawano K, et al. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol 1997; 30: 91-6.
16. Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vase Biol 1996; 16: 948-54.
17. Saku K, Ahmad M, Greenwalt-Glas P, Khashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985; 39: 1-8.
18. Bajzar L, Manuel R, Nesheim M. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
19. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascade through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
20. Bouma BN, von den Borme PAK, Meijers JCM. Factor XI and protection of the fibrin clot against lysis - a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80: 24-7.
21. Silveira A, Schatteman K, Goossens F, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
22. Stiko A, Hervio L, Loskutoff DJ. Plasminogen activator inhibitors. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and thrombosis, basic principles and clinical practice. 4th edition. Philadelphia, PA: Lippincott Williams and Wilkins, 2001: 355-66.
23. Carter AM, Grant PJ. To lyse or not to lyse? Is it genetic? Ital Heart J 2001; 2: 652-5.
24. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-51.
25. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-80.
26. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-6.
27. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
28. Ceriello A, Pirisi M, Giacomello R, et al. Fibrinogen plasma levels as marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost 1994; 71: 593-5.
29. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76.
30. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost 1990; 63: 331-5.
31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-503.
32. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237-40.
33. Ferroni P, Speziale G, Ruvolo G, et al. Platelet activation and cytokine production during hypothermic cardiopulmonary bypass. A possible correlation? Thromb Haemost 1998; 80: 58-64.
34. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52.
35. Schatteman KA, Goossens FJ, Scharpé S, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-13.
36. Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Intern Med 1994; 236: 425-32.
37. Avellone G, Di Garbo V, Cordova R, et al. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. Blood Coagul Fibrinolysis 1995; 6: 543-8.
38. Bloomfield Rubins H, Robins JA, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
39. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implication for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
40. Kearney D, Fitzgerald D. The anti-thrombotic effects of statins. J Am Coll Cardiol 1999; 33: 1305-7.
41. Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolus. Circulation 1999; 99: 299-304.
42. Mosnier LO, Meijers JCM, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5-11.
43. Braaten JV, Handt S, Jerome W, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-9.
44. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15: 2073-84.
45. Bröijersen A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1996; 16: 511-6.
46. Hamsten A, Syvänne M, Silveira A, et al. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy. Thromb Haemost 2000; 83: 397-403.
47. Juhan-Vague I, Vague P, Alessi MC, et al. Relationships between plasma insulin triglyceride, body mass index and plasminogen activator inhibitor 1. Diabete Metab 1987; 13: 331-6.